Reviva Pharmaceuticals Holdings, Inc. (RVPH)
|Net Income (ttm)||-3.78M|
|Trading Day||May 14|
|Day's Range||4.69 - 5.00|
|52-Week Range||3.93 - 15.10|
Today, investors in RVPH stock saw some pretty massive gains, as the company announced impressive results for its schizophrenia drug. The post RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% ...
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) more than doubled in value Monday after the clinical-stage biopharmaceutical company reported encouraging phase 2 clinical trial results fo...
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced the full details of its Phase 2 trial evaluating its lead drug candidate, RP5063 (brilaroxazine), for Acute Schizophrenia. Brilaroxazine ...
CUPERTINO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical compa...
-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market-
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Ph...
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Tenzing Acquisition Corp.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tenzi...
New York, New York--(Newsfile Corp. - July 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who own Tenzing Acquisition Corp.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and ps... [Read more...]
|Stock Exchange |
|Ticker Symbol |